Abstracts tagged "Biologics and treatment"

Abstract Number: 1540 • 2019 ACR/ARP Annual Meeting
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Atul Deodhar ¹, Theresa Hunter², Elizabeth Holdsworth ³, Nicola Booth ⁴ and David Sandoval ⁵, ¹Oregon Health & Science University, Portland, OR, ²Eli Lilly and Company, Indianapolis, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The FDA approved the first biologic for the treatment of nr-axSpA in the US in March 2019. The objective of our study was to…
Abstract Number: 2857 • 2019 ACR/ARP Annual Meeting
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Emma Hernlund ¹, Johan Klint ¹, Axel Svedbom ¹, Johan Dalén ¹, Christopher Black ² and Amy Puenpatom², ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Merck & Co., Inc., Kenilworth, NJ, United States, Kenilworth, NJ
Background/Purpose: The advent of biologic medications, such as subcutaneous TNF-alpha inhibitors (SC-TNFi), has transformed the management of inflammatory arthritis (IA) during the last decades. However,…